Comparing Guardant Health (NASDAQ:GH) and Amplifon (OTCMKTS:AMFPF)

Amplifon (OTCMKTS:AMFPF) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Amplifon and Guardant Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amplifon	0	2	3	0	2.60
Guardant Health	1	0	24	1	2.96

Guardant Health has a consensus target price of $188.12, suggesting a potential upside of 18.30%. Given Guardant Health’s stronger consensus rating and higher probable upside, analysts clearly believe Guardant Health is more favorable than Amplifon.

Valuation and Earnings

This table compares Amplifon and Guardant Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amplifon	$2.71 billion	0.91	$103.33 million	$0.37	30.30
Guardant Health	$982.02 million	21.73	-$416.28 million	($3.49)	-45.57

Amplifon has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Amplifon, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amplifon has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Profitability

This table compares Amplifon and Guardant Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amplifon	3.01%	15.03%	4.29%
Guardant Health	-38.33%	N/A	-25.40%

Institutional and Insider Ownership

92.6% of Guardant Health shares are held by institutional investors. 5.6% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Guardant Health beats Amplifon on 8 of the 15 factors compared between the two stocks.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.